0001104659-19-071119.txt : 20191209
0001104659-19-071119.hdr.sgml : 20191209
20191209210032
ACCESSION NUMBER: 0001104659-19-071119
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191205
FILED AS OF DATE: 20191209
DATE AS OF CHANGE: 20191209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McBarron Paul
CENTRAL INDEX KEY: 0001357397
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50626
FILM NUMBER: 191276396
MAIL ADDRESS:
STREET 1: C/O CYCLACEL PHARMACEUTICALS, INC.
STREET 2: 200 CONNELL DRIVE, SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001130166
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911766850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
BUSINESS PHONE: 908-517-7330
MAIL ADDRESS:
STREET 1: 200 CONNELL DRIVE
STREET 2: SUITE 1500
CITY: BERKELEY HEIGHTS
STATE: NJ
ZIP: 07922
FORMER COMPANY:
FORMER CONFORMED NAME: XCYTE THERAPIES INC
DATE OF NAME CHANGE: 20001218
4
1
tm1924755d1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2019-12-05
0
0001130166
Cyclacel Pharmaceuticals, Inc.
CYCC
0001357397
McBarron Paul
200 CONNELL DRIVE, SUITE 1500
BERKELEY HEIGHTS
NJ
07922
1
1
0
0
E. VP, Fin, CFO and COO
Option
1.74
2019-12-05
4
A
0
13022
0
A
2027-12-29
Common Stock
13022
13022
D
Option
1.56
2019-12-05
4
A
0
11980
0
A
2028-02-22
Common Stock
11980
11980
D
On December 29, 2017, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 13,022 shares.
On February 22, 2018, Paul McBarron was granted an option to purchase certain shares of common stock, which option shall vest according to the satisfaction of performance criteria. Certain performance criteria were confirmed to have been met on December 5, 2019, resulting in the vesting of the option as to 11,980 shares.
/s/ Paul McBarron
2019-12-09